{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-014332","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.376657+00:00","generated_at":"2026-06-06T01:10:26.231494+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius Pharma Q1 net loss $9.2M; cash runway through Aug 2024","bullets":["Net loss of $9.2M ($0.06 per share) compared to loss of $3.6M ($0.02 per share) in prior year.","Cash and equivalents $20.3M as of Dec 31, 2023; runway expected through August 2024.","LYMPHIR BLA resubmitted to FDA; awaiting PDUFA date; merger of oncology subsidiary with TenX (TENK) expected H1 2024.","Completed enrollment in Mino-Lok Phase 3 trial; topline results expected in Q2 2024.","R&D expenses $2.6M (down from $3.4M); G&A expenses $3.7M (up from $2.6M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-014332","json":"https://secwatch.observer/filing/0001213900-24-014332.json","markdown":"https://secwatch.observer/filing/0001213900-24-014332.md","text":"https://secwatch.observer/filing/0001213900-24-014332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024014332/0001213900-24-014332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024014332/ea193774-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:10:26.231494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06f508e53397fd811a6287e502c55fd5a8c5c2c0","claim":"Citius Pharmaceuticals, Inc. reported first quarter of fiscal 2024 results: net income $9.2 million, or ($0.06) per share, EPS ($0.06) per share.","evidence_excerpt":"On February 14, 2024, we issued a press release announcing our results of operations for the first quarter of fiscal 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024014332/0001213900-24-014332-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal 2024"},{"label":"Net income","value":"$9.2 million, or ($0.06) per share"},{"label":"EPS","value":"($0.06) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}